Medicina de Familia SEMERGEN, Год журнала: 2023, Номер 50(3), С. 102129 - 102129
Опубликована: Ноя. 17, 2023
Medicina de Familia SEMERGEN, Год журнала: 2023, Номер 50(3), С. 102129 - 102129
Опубликована: Ноя. 17, 2023
The Journal of Dermatology, Год журнала: 2024, Номер unknown
Опубликована: Сен. 3, 2024
Abstract Prurigo nodularis (PN) is a chronic inflammatory skin disease associated with intense pruritic nodules. The unclear patho‐etiological mechanisms of PN cause difficulty in management; and there paucity information on the current diagnosis treatment options for Japan. To describe management from dermatologists' perspective we conducted web‐based survey (UMIN Clinical Trial Registry UMIN000047643) 2022 among dermatologists Japanese commercially available physician panel, who had seen at least one patient within last 3 months. included 117 dermatologists. diagnosed mainly by confirming clinical signs interviews, while to assess severity PN, number nodules degree itching were primarily utilized. Topical corticosteroids antihistamines most used drugs, as recommended guidelines prurigo. Dermatologists' satisfaction decreased increasing assumed PN; almost 65% not satisfied severe PN. These results suggest need more effective medications diagnostic tools better
Язык: Английский
Процитировано
1Allergy Asthma and Immunology Research, Год журнала: 2024, Номер 16(5), С. 546 - 546
Опубликована: Янв. 1, 2024
Prurigo nodularis (PN) is a chronic neuroinflammatory dermatosis with severe pruritus that has limited efficacy in various conventional treatments. This study investigated the outcomes of upadacitinib treatment patients refractory PN. A prospective was conducted to screen for potential infections prior treatment. Upadacitinib administered at daily dose 15 mg 24 weeks, and response assessed using itch Numeric Rating Scale (NRS), investigator's Global Assessment (IGA), Dermatology Life Quality Index (DLQI). Adverse events were monitored each visit. Ten patients, an average age 48.8 years, included study. All participants treated systemic cyclosporine before receiving upadacitinib, which yielded responses. At baseline, mean prurigo severity scores IGA, DLQI, NRS 3.4, 17.8, 8.1, respectively; after weeks treatment, these significantly reduced 1.0, 0.6, 0.8, respectively. No adverse effects observed. In conclusion, could be considered alternative therapeutic option good tolerability
Язык: Английский
Процитировано
1Actas Dermo-Sifiliográficas, Год журнала: 2023, Номер 114(7), С. 613 - 626
Опубликована: Март 31, 2023
El prurito es el síntoma principal en múltiples enfermedades dermatológicas y sistémicas. La dermatitis atópica, la psoriasis, de contacto, urticaria, liquen simple crónico, micosis fungoides, las cicatrices, autoinmunes, enfermedad renal o hepática crónica, entre otras, asocian que puede requerir un manejo terapéutico distinto. Aunque los antihistamínicos parecen ser primera línea tratamiento, realidad su papel queda limitado a urticaria reacciones por fármacos, ya mecanismos fisiopatológicos cada una entidades tratadas lo largo este manuscrito serán distintas. En estos últimos años han aparecido nuevas moléculas para tratamiento del prurito, con perfiles eficacia seguridad muy atractivos uso práctica clínica. Sin duda, momento crucial desarrollo dermatología campo oportunidad más exigentes objetivos alcanzar pacientes. Pruritus is the main symptom of many dermatologic and systemic diseases. Atopic dermatitis, contact lichen simplex chronicus, mycosis scars, autoimmune diseases, kidney or liver diseases among others are all associated with itch that may require different approaches to management. Although antihistamines seem be first line therapy, in reality their role limited drug-induced reactions. In fact, pathophysiologic mechanisms each conditions covered this review will differ. Recent years have seen emergence new drugs whose efficacy safety profiles very attractive for management pruritus clinical practice. Clearly we at critical moment dermatology, which chance more ambitious our goals when treating patients pruritus.
Процитировано
3Acta Dermato Venereologica, Год журнала: 2024, Номер 104, С. adv15771 - adv15771
Опубликована: Фев. 1, 2024
Abstract is missing (Short communication)
Язык: Английский
Процитировано
0Folia Medica Indonesiana, Год журнала: 2024, Номер 60(1), С. 47 - 53
Опубликована: Март 10, 2024
Highlights:1. An examination of IL-4 and IL-5 expressions in nodular prurigo pruritic papular eruption is crucial for enhancing the effectiveness biological agent therapy, specifically HIV/AIDS patients.2. The findings offer evidence suggesting possibility as a treatment target individuals diagnosed with prurigo, well those eruption. AbstractPruritic dermatosis characterized by symptoms patients human immunodeficiency virus/acquired syndrome (HIV/AIDS). Similarly, an itchy lesions histopathological features that resemble Both conditions share common etiopathogenesis, which involves cytokines produced T helper 2 (Th2) cells. Nodular are chronic frequently recalcitrant, thus posing challenges treatment. use agents represents development recalcitrant dermatoses. This study aimed to determine difference mean percentage interleukin-4 (IL-4) interleukin-5 (IL-5) between lesions, may establish basis further therapy. A cross-sectional was conducted using paraffin block preparations skin (n=16) (n=16). Each preparation involved immunohistochemical staining monoclonal antibodies. were assessed through ImageJ Windows, version 1.53 (National Institutes Health Laboratory Optical Computational Instrumentation, University Wisconsin, USA) pathologists. data analyzed unpaired t-test significance level p<0.05. analytical results indicated on average age two groups, disease duration, storage sample duration followed normal distribution (p>0.05). expression significantly different groups (p=0.000). However, not (p=0.060). In conclusion, higher group comparison group. Nonetheless, comparably high both groups.
Язык: Английский
Процитировано
0Enfermería Clínica, Год журнала: 2024, Номер unknown
Опубликована: Авг. 1, 2024
Se presenta el caso clínico de un hombre 87 años con prurigo crónico sin tratamiento cutáneo. El objetivo es aplicar plan cuidados individualizado que permita, basándose en las últimas evidencias, conseguir la integridad cutánea al encontrarse deteriorada y así mejorar su calidad vida debido fracaso actual del abordaje patología. identificaron varias etiquetas diagnósticas NANDA Internacional utilizando herramienta online NNNConsult se planificaron los resultados esperados junto intervenciones enfermeras planificadas. muestra dificultad intrínseca una patología multifactorial poco conocida frecuente pero conlleva notable afectación cuando, además, actualidad están emergiendo nuevos abordajes tratamientos inexplorados por pacientes profesionales. Esta situación hace necesaria exposición formación casos como presenta, actualización vías tratamiento, implicación real profesionales para adaptación, individualización búsqueda continua suplir necesidades problemas padecen personas a cuidamos, necesidad conocer enfoques cutáneos. Este trabajo traza línea cutáneos respetuosos cutánea, siguiendo señala terapéutico médico profundizar, no ser ni competencia enfermería. We present the clinical case of an 87-year-old man who presents with chronic without skin treatment. The aim is to apply individualized care that allows, based on latest evidence, achieve integrity, which deteriorated, and improve its quality life due current failure toad dress pathology. Several International diagnostic labels were identified using tool expected outcomes along planned nursing interventions. shows intrinsic difficulty pathology little known rare but entails impact especially when new treatment approaches are currently emerging explored by patients professionals. This situation makes it necessary expose train cases like one presented, update path ways, involvement professionals for adaptation, individualization continuous search meet needs problems suffered people we for, as well need know approaches. work outlines line respects following points out therapeutic medical approach going into depth not or competence.
Процитировано
0Acta Dermato Venereologica, Год журнала: 2024, Номер 104, С. adv40677 - adv40677
Опубликована: Авг. 5, 2024
Abstract is missing (Short communication)
Язык: Английский
Процитировано
0Enfermería Clínica (English Edition), Год журнала: 2024, Номер 34(6), С. 507 - 513
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
0Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, Год журнала: 2024, Номер unknown, С. 477 - 482
Опубликована: Янв. 1, 2024
Atopic skin plays a significant etiological role in the development of prurigo nodularis (PN). In addition to atopic dermatitis (AD), diathesis without eczema can also contribute PN due its association with itching. This study aims evaluate terms AD/atopic diathesis, associated comorbidities, and clinical findings. Patients diagnosed based on histopathological findings between 2014 2024 were included study. Associated diseases that could etiology pruritus recorded as comorbidities. The diagnosis AD was evaluated using Hanifin-Rajka's diagnostic criteria Erlangen Atopy Score. classified non-atopic groups, these groups compared demographic total 47 patients, whom 15 (31.9%) male 32 (68.1%) female. At least one comorbidity identified 89.4% (n=42) multiple comorbidities found 34% (n=16). and/or present 55.3% (n=26) patients. Among these, 53.8% (n=14) AD, while 46.2% (n=12) had only an diathesis. Compared group, group lower median age (p=0.001) higher serum IgE levels (p=0.031). appears play important PN. patients are factors predisposition.
Язык: Английский
Процитировано
0